GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC
This article was originally published in The Pink Sheet
Executive Summary
GSK gains approval of sNDA for Rx Veramyst (fluticasone furoate/spray) to be marketed OTC as Flonase Sensimist, an extension of the Flonase Allergy Relief.
You may also be interested in...
Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space
ClariSpray is the same formulation as GSK Consumer Healthcare's Flonase Allergy Relief, but Bayer is not making all of the same claims because OTC Flonase for another year has exclusivity among OTC intranasal corticosteroids for eye-related allergy relief.
Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals
OTC drugs with single brand for various line extensions might confuse patients, agency says. Findings could have implications for Rx risk communication as well.
Rhinocort Switch Makes Three In OTC Intranasal Corticosteroid Market
CDER’s approval of McNeil’s supplemental NDA for the budesonide spray came without an advisory committee opinion, a step the agency required for the first switch in the category, Glaxo’s Flonase Allergy Relief. OTC Rhinocort is indicated for temporary relief of symptoms of hay fever or other upper respiratory allergies in adults and children ages 6 and up, with separate directions for use by children ages 6 to 12.